ALVOW Alvotech - Warrant
0.3700USD0.00%Mkt Cap: —P/E: —7d ago
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)494.61M USD
Gross Profit350.76M USD
Net Income (TTM)27.92M USD
Revenue/Share1.68 USD
Last Price0.3700 USD
Fiscal Year End—
MR Quarter—
Employees1.3K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.84
EPS (TTM)—
EPS (Forward)—
52W Range
0.220156% of range0.4900
52W High0.4900 USD
52W Low0.2201 USD
Profitability
Gross Margin59.82%
Oper. Margin-11.05%
EBITDA Margin15.31%
Profit Margin4.76%
ROE-9.81%
ROA1.88%
Growth
Revenue Growth-38.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-50.20M USD
CapEx (TTM)96.13M USD
FCF Margin-24.89%
FCF Yield—
Net Debt1.31B USD
Net Debt/EBITDA17.28
Balance Sheet
Debt/Equity-5.09
Current Ratio1.65
Quick Ratio0.79
Book Value/Sh-0.54 USD
Cash/Share0.40 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float140.79M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta0.20
S&P 52W Chg15.78%
Avg Vol (30d)2.40K
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—